The industry’s first ALK degrader starts its first human study.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
One first-in-human study and two deals in a single day sees companies blaze the ADC trail.
CuraDev and OncoNano move into phase 1, trying to avoid the negative precedent of other Sting agonist projects.
Seagen/Genmab’s confirmatory cervical cancer trial is toplined positive, putting up a fresh roadblock for Iovance’s accelerated filing plans.
Palazestrant joins vepdegestrant in pivotal development, as SERDs continue their rollercoaster ride.
The company’s radiopharmaceutical PNT2002 faces a major fourth-quarter catalyst, and US filing could follow.
Novartis looks set to hand nisevokitug rights back to Xoma, though plenty of work on TGF-β continues.